Course Detail

Immunization of Health-care Personnel: Recommendations of the Advisory Committee on Immunization Practices (ACIP)

Course Number: WB1945-11252011

CE Origination Date: November 25, 2011

CE Expiration Date: November 25, 2013

Goal

This activity will change the impact of competence and patient /client outcome by assisting hospital administrators, infection control practitioners, employee health clinicians, and HCP in Optimizing infection prevention and control programs. Disease- specific outbreak control measures are described in this report. Nationwide, ongoing implementation of these vaccine recommendations through well-managed vaccination programs could substantially reduce both the number of susceptible HCP in any setting in which they interact with patients and their risks for transmitting vaccine-preventable diseases to other personnel and patients.

Objectives

- 1. Describe the term "health-care personnel" and the settings in which these recommendations would apply
- 2. Describe those diseases for which vaccinations or documentation of immunity is recommended
- 3. Identify the changes from the previously published recommendations (1997)
- 4. Describe vaccine-specific recommendations for those vaccines recommended for all HCP and those that might be indicated in certain circumstances

Intended Audience

Physicians, Registered Nurses, Administrators, Infection control practitioners, employee health clinicians, health-care personnel

Content Experts/Prepares

William Atkinson, MD, MPH, Medical Epidemiologist, NCIRD, CDC Stephanie R. Bialek, MD, MPH, Epidemiologist, NCIRD/CDC Amanda Cohn, MD, Medical Epidemiologist, NCIRD/CDC Amy Parker Fiebelkorn, MSM, MPH, Epidemiologist, NCIRD, CDC Anthony Fiore, MD, Medical Epidemiologist, NCGH, CDC Carole Friedman, DO, Epidemiologist, NCIRD, CDC Lisa Grohskopf, MD, MPH, Medical Officer, NCIRD, CDC David T. Kuhar, MD, Medical Officer, NCEZID, CDC Jennifer Liang, DVM, MPVM, Epidemiologist, NCIRD, CDC Suchita A. Lorick, DO, Medical Officer, NCIRD, CDC

Mona Martin, MD, Medical Epidemiologist, NCIRD, CDC
Eric Mintz, MD, MPH, Team Lead, Global WASH Epidemiology, NCEZID, CDC
Gina Mootrey, DO, MPH, Associate Director for Science, NCIRD, CDC
Trudy V. Murphy, MD, Medical Epidemiologist, Team Lead, Vaccine Unit, NCHHSTP, CDC
Anna Newton, MPH, Surveillance Epidemiologist, NCEZID, CDC
Jane F. Seward, MBBS, MPH, Deputy Director, Division of Viral Diseases, NCIRD, CDC
Abigail Shefer, MD, Associate Director for Science, NCIRD, CDC
Gregory Wallace, MD, MS, MPH, Medical Officer, NCIRD, CDC

ACCREDITATION STATEMENTS:

CME: The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

The Centers for Disease Control and Prevention designates this web based activity for a maximum of **2.0** *AMA PRA Category 1 Credits* $^{\text{\tiny IM}}$. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Non-physicians will receive a certificate of participation.

CNE: The Centers for Disease Control and Prevention is accredited as a provider of Continuing Nursing Education by the American Nurses Credentialing Center's Commission on Accreditation.

This activity provides **1.8** contact hours.

CEU: The CDC has been approved as an Authorized Provider by the International Association for Continuing Education and Training (IACET), 1760 Old Meadow Road, Suite 500, McLean, VA 22102. The CDC is authorized by IACET to offer **0.2** ANSI/IACET CEU's for this program.

CECH: Sponsored by the *Centers for Disease Control and Prevention,* a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designed for Certified Health Education Specialists (CHES) to receive up to **2.0** Category I CECH in health education. CDC provider number **GA0082**.

DISCLOSURE

In compliance with continuing education requirements, all presenters must disclose any financial or other associations with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters as well as any use of unlabeled product(s) or product(s) under investigational use.

CDC, our planners, and our presenters wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters.

This report will not include any discussion of the unlabeled use of a product or a product under investigational use with the exception of the following situations:

- 1. For varicella postexposure prophylaxis for persons without evidence of immunity who have contraindications for vaccination and who are at risk for severe disease and complications, the product currently used in the United States, VariZIG (Cangene Corporation, Winnipeg, Canada), is available under an Investigational New Drug Application Expanded Access Protocol.
- 2. The interval between administration of Td and Tdap might be <5 years as indicated in package insert.
- 3. One Tdap product, Adacel (sanofi pasteur, Toronto, Canada), is labeled for use in persons aged 11–64 years. The other Tdap product, Boostrix (GlaxoSmithKline Biologicals, Rixensart, Belgium), is labeled for use in persons aged ≥10 years. Until ACIP reviews the current recommendations on use of Tdap in persons aged ≥65 years, either Tdap product may be used in persons aged ≥65 years.
- 4. Meningococcal conjugate vaccines are licensed only as a single dose .The 2-dose series of meningococcal conjugate vaccine is recommended for persons with certain medical risk factors, and the booster dose of meningococcal

CDC does not accept commercial support.

Technical Support

To take exam please go to www.cdc.gov/TCEOnline, click on Search and type in MMWR under Option 2.

Your browser must be Internet Explorer 7.0